| Gemcitabine studied in …STUDIED_INderived200 of 2,012show all (up to 200) |
|---|
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · 2,012 trials list this drug (440 active) | — | — | Lymphoma,Hodgkin Lymphoma,Chronic Myelomonocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03734029Phase 3 · completed Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] · 2,012 trials list this drug (440 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 2,012 trials list this drug (440 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05712356Phase 2 · completed A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma,Malignant Bile Duct Neoplasm,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06619236Phase 3 · active not recruiting Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer · 2,012 trials list this drug (440 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06623422Phase 3 · recruiting A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06694454Phase 1/Phase 2 · suspended Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06770582Phase 2 · recruiting Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm,Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788912Phase 2 · active not recruiting Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06919965Phase 3 · recruiting A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07498907Phase 3 · recruiting Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma · 2,012 trials list this drug (440 active) | — | — | Renal Pelvis and Ureter Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · 2,012 trials list this drug (440 active) | — | — | Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma,Pancreatic Adenosquamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03093922Phase 2 · completed A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Non-Small Cell Squamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04628767Phase 2/Phase 3 · recruiting Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04658862Phase 3 · active not recruiting A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder · 2,012 trials list this drug (440 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05139017Phase 2/Phase 3 · recruiting A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) · 2,012 trials list this drug (440 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389514no longer available Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06103864Phase 3 · recruiting A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) · 2,012 trials list this drug (440 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06211764Phase 3 · active not recruiting A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) · 2,012 trials list this drug (440 active) | — | — | Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06308419Phase 1 · active not recruiting A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions · 2,012 trials list this drug (440 active) | — | — | Soft Tissue Sarcoma,Leiomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06312137Phase 3 · recruiting A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06319820Phase 3 · recruiting A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06545955Phase 3 · recruiting A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929624Phase 3 · active not recruiting A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007559Phase 2 · recruiting ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07259317Phase 2 · recruiting Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Carcinoma,Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03618550Phase 2 · recruiting Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma · 2,012 trials list this drug (440 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445062Phase 1/Phase 2 · recruiting Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Malignant Digestive System Neoplasm,Colorectal Carcinoma,Malignant Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06524544Phase 3 · recruiting A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07213804Phase 3 · recruiting A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer · 2,012 trials list this drug (440 active) | — | — | Peritoneal Neoplasm,Fallopian Tube Neoplasm,Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528768Phase 2 · not yet recruiting HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07769502Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers · 2,012 trials list this drug (440 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216316Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04543071Phase 2 · active not recruiting Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Adenocarcinoma,Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06375915Phase 2 · recruiting Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07111546Phase 2 · recruiting A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829783Phase 3 · not yet recruiting A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831993Phase 2 · recruiting Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06227065Phase 2 · not yet recruiting Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828756Phase 2 · not yet recruiting Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00421096Phase 2 · terminated Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer · 2,012 trials list this drug (440 active) | — | — | Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02436707Phase 2 · active not recruiting Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06629597Phase 3 · active not recruiting A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07043972Phase 2 · recruiting Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07173751Phase 3 · recruiting ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer · 2,012 trials list this drug (440 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07332351Phase 2 · not yet recruiting Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm,Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824856Phase 2 · not yet recruiting Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07824986Phase 3 · not yet recruiting A Phase 3 Trial in Advanced Epithelioid Mesothelioma · 2,012 trials list this drug (440 active) | — | — | Malignant Mesothelioma,Pleural Mesothelial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01352962Phase 1 · completed Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Urethra Neoplasm,Malignant Urethral Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579224Phase 3 · active not recruiting Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05786924Phase 1/Phase 2 · recruiting Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm,Histiocytic and Dendritic Cell Neoplasm,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029270Phase 2 · recruiting Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07492680Phase 2 · recruiting A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07532902Phase 1 · recruiting A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797881Phase 2 · not yet recruiting A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538663Phase 3 · active not recruiting Intravesical BCG vs GEMDOCE in NMIBC · 2,012 trials list this drug (440 active) | — | — | Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619235Phase 4 · recruiting A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07783321Phase 3 · not yet recruiting A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07821177early Phase 1 · active not recruiting Bladder Preservation or Cystectomy for MIBC · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm,Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03533582Phase 3 · active not recruiting Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery · 2,012 trials list this drug (440 active) | — | — | Hepatoblastoma,Hepatocellular Malignant Neoplasm, Not Otherwise Specified,Childhood Hepatocellular Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191135Phase 2 · terminated Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04559139Phase 2/Phase 3 · active not recruiting Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Gallbladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06064097Phase 2 · recruiting A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282575Phase 3 · recruiting Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07491445Phase 3 · recruiting Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma,Pancreatic Adenosquamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07818499Phase 1/Phase 2 · not yet recruiting A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01585805Phase 2 · active not recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06806033Phase 2 · recruiting Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06843447Phase 1/Phase 2 · recruiting A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07566156Phase 3 · recruiting Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) · 2,012 trials list this drug (440 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743164Phase 3 · not yet recruiting A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) · 2,012 trials list this drug (440 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 2,012 trials list this drug (440 active) | — | — | Ovarian Brenner Tumor,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02135042Phase 2/Phase 3 · active not recruiting Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03661320Phase 3 · completed A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04310007Phase 2 · active not recruiting Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07308132Phase 1 · recruiting A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · 2,012 trials list this drug (440 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07780838Phase 2 · recruiting Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma · 2,012 trials list this drug (440 active) | — | — | Biliary Tract Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01660971Phase 1 · active not recruiting Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery · 2,012 trials list this drug (440 active) | — | — | Pancreatic Carcinoma,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595892Phase 2 · active not recruiting Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 2,012 trials list this drug (440 active) | — | — | Ovarian Serous Tumor,Primary Peritoneal Carcinoma,Ovarian Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · 2,012 trials list this drug (440 active) | — | — | Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907475Phase 2 · recruiting Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial · 2,012 trials list this drug (440 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04104672Phase 1 · completed A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05685602Phase 1 · suspended CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06037980Phase 2/Phase 3 · recruiting CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06548412Phase 1/Phase 2 · recruiting CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06897644Phase 3 · recruiting Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. · 2,012 trials list this drug (440 active) | — | — | Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07604766Phase 3 · recruiting An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China · 2,012 trials list this drug (440 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00878163Phase 1 · active not recruiting GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery · 2,012 trials list this drug (440 active) | — | — | Adult Solid Neoplasm,Pancreatic Neoplasm,Pancreatic Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04577014Phase 1/Phase 2 · recruiting Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma · 2,012 trials list this drug (440 active) | — | — | Sarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06624085Phase 1 · recruiting A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07189793Phase 2 · not yet recruiting Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study · 2,012 trials list this drug (440 active) | — | — | Transitional Cell Carcinoma,Bladder Neoplasm,Bladder Urothelial Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07805954Phase 3 · recruiting Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma,Pancreatic Adenosquamous Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07808216Phase 2 · not yet recruiting Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06050252Phase 2 · suspended Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390059Phase 2 · completed EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178552Phase 2/Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892953Phase 2 · recruiting Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07684612Phase 3 · not yet recruiting A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) · 2,012 trials list this drug (440 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07801027Phase 4 · not yet recruiting A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) · 2,012 trials list this drug (440 active) | — | — | Malignant Neoplasm,Gastric Neoplasm,Biliary Tract Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07802184Phase 1/Phase 2 · not yet recruiting GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06608927Phase 3 · active not recruiting Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06632327Phase 3 · active not recruiting Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855225Phase 2 · not yet recruiting A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma · 2,012 trials list this drug (440 active) | — | — | Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07024615Phase 1 · recruiting A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer · 2,012 trials list this drug (440 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03547973Phase 2 · active not recruiting Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05279300Phase 1 · suspended A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05508867Phase 2 · completed A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) · 2,012 trials list this drug (440 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07564141Phase 3 · recruiting Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797153Phase 3 · not yet recruiting JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03652428Phase 1/Phase 2 · active not recruiting Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793942Phase 2 · not yet recruiting A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03775265Phase 3 · active not recruiting Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm,Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06459180Phase 3 · active not recruiting A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) · 2,012 trials list this drug (440 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365306Phase 2 · recruiting Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06313970Phase 2 · active not recruiting First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06958328Phase 3 · recruiting Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02991482Phase 3 · completed PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03257033Phase 3 · recruiting Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05104866Phase 3 · active not recruiting A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) · 2,012 trials list this drug (440 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05775159Phase 2 · active not recruiting Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer · 2,012 trials list this drug (440 active) | — | — | Hepatocellular Carcinoma,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05979298Phase 2 · completed Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Ovarian Neoplasm,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586515Phase 1 · recruiting MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05548296Phase 2 · recruiting A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Endometrial Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254899Phase 2 · completed A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) · 2,012 trials list this drug (440 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06027268Phase 2 · active not recruiting Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06741644Phase 1/Phase 2 · recruiting A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06929286Phase 3 · recruiting A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07021989Phase 2 · recruiting ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · 2,012 trials list this drug (440 active) | — | — | Hodgkin Lymphoma,Adult Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07129993Phase 2/Phase 3 · recruiting Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07275216Phase 2 · recruiting Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment · 2,012 trials list this drug (440 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07283705Phase 2 · recruiting A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07619313Phase 1 · recruiting AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Cholangiocarcinoma,Pancreatic Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04999969Phase 2 · active not recruiting Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06467357Phase 3 · recruiting Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06792253Phase 3 · recruiting Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774234Phase 2 · not yet recruiting Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06685796Phase 2 · completed A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097142Phase 3 · recruiting Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm,Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07544056Phase 2/Phase 3 · recruiting A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04865939Phase 3 · recruiting Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04891289Phase 2 · recruiting Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06048133Phase 2 · active not recruiting Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) · 2,012 trials list this drug (440 active) | — | — | Biliary Tract Carcinoma,Malignant Bile Duct Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07767994Phase 2 · not yet recruiting AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Gallbladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768943Phase 2 · not yet recruiting GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Nasal Type Extranodal NK/T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07765433Phase 2/Phase 3 · not yet recruiting Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma,Biliary Tract Adenocarcinoma,Extrahepatic Cholangiocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05211323Phase 2 · active not recruiting A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer · 2,012 trials list this drug (440 active) | — | — | Combined Hepatocellular Carcinoma and Cholangiocarcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07570823Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 2,012 trials list this drug (440 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04115163Phase 2 · active not recruiting Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06139211Phase 1/Phase 2 · completed A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587662Phase 2 · completed Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer · 2,012 trials list this drug (440 active) | — | — | Renal Cell Carcinoma,Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656536Phase 3 · terminated A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma · 2,012 trials list this drug (440 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04164082Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm,Bladder Flat Urothelial Carcinoma In Situ,Non-Muscle Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04179162Phase 1/Phase 2 · active not recruiting Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment · 2,012 trials list this drug (440 active) | — | — | Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594772Phase 2 · active not recruiting Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma · 2,012 trials list this drug (440 active) | — | — | Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07420439Phase 2 · not yet recruiting Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06576115Phase 2 · recruiting Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06926868Phase 2/Phase 3 · recruiting A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) · 2,012 trials list this drug (440 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05999994Phase 2 · recruiting A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer · 2,012 trials list this drug (440 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07748611Phase 2 · not yet recruiting SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial · 2,012 trials list this drug (440 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04999761Phase 1 · recruiting AB122 Platform Study · 2,012 trials list this drug (440 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171647Phase 3 · active not recruiting A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma · 2,012 trials list this drug (440 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07000084Phase 3 · recruiting Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm,Non-Muscle Invasive Bladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04083599Phase 1/Phase 2 · active not recruiting GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Malignant Solid Neoplasm,Melanoma,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06960577Phase 3 · recruiting Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) · 2,012 trials list this drug (440 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03662074Phase 2 · terminated Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03869190Phase 1/Phase 2 · terminated Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05285358Phase 1 · recruiting Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases · 2,012 trials list this drug (440 active) | — | — | Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm,Gallbladder Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07741448Phase 2 · recruiting Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 2,012 trials list this drug (440 active) | — | — | Ovarian Endometrioid Tumor,Ovarian Serous Tumor,Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627443Phase 1 · active not recruiting Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 2,012 trials list this drug (440 active) | — | — | Ovarian Endometrioid Tumor,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491942Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Solid Neoplasm,Breast Carcinoma,Head and Neck Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05382559Phase 1 · recruiting A Study of ASP3082 in Adults With Advanced Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03259503Phase 1 · completed Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant · 2,012 trials list this drug (440 active) | — | — | Hodgkin Lymphoma,T-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04657068Phase 1/Phase 2 · recruiting A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors · 2,012 trials list this drug (440 active) | — | — | Malignant Neoplasm,Acinar Cell Carcinoma,Malignant Fallopian Tube Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06457503Phase 4 · recruiting A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer · 2,012 trials list this drug (440 active) | — | — | Nasopharyngeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02486718Phase 3 · active not recruiting Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03425643Phase 3 · active not recruiting Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04198766Phase 1/Phase 2 · recruiting Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) · 2,012 trials list this drug (440 active) | — | — | Solid Neoplasm,Malignant Head and Neck Neoplasm,Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06219941Phase 2 · recruiting AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 · 2,012 trials list this drug (440 active) | — | — | Malignant Gastric Neoplasm,Malignant Biliary Tract Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07106762Phase 2/Phase 3 · recruiting Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy · 2,012 trials list this drug (440 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07255404Phase 2 · recruiting A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05141149Phase 1/Phase 2 · active not recruiting First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05616624Phase 1/Phase 2 · terminated ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers · 2,012 trials list this drug (440 active) | — | — | Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07444541Phase 1/Phase 2 · recruiting ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252887Phase 2 · completed Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy · 2,012 trials list this drug (440 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02905578Phase 2 · completed A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) · 2,012 trials list this drug (440 active) | — | — | Adenocarcinoma,Malignant Pancreatic Neoplasm,Pancreatic Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026657Phase 1/Phase 2 · recruiting Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer · 2,012 trials list this drug (440 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06343948Phase 3 · active not recruiting A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01) · 2,012 trials list this drug (440 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06382142Phase 3 · active not recruiting A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) · 2,012 trials list this drug (440 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02711553Phase 2 · active not recruiting A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Neoplasm,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03924856Phase 3 · completed Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) · 2,012 trials list this drug (440 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04521686Phase 1 · active not recruiting Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations · 2,012 trials list this drug (440 active) | — | — | Chondrosarcoma,Glioma,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05911295Phase 3 · active not recruiting Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 · 2,012 trials list this drug (440 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816358Phase 1 · active not recruiting Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer · 2,012 trials list this drug (440 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |